However, the ability to modulate the aggregation process by altering Sph1 expression or disrupting the Sph1-aSyn interaction paves the way for testing and screening putative therapeutic strategies for PD and related synucleinopathies. This evidence concerns the gene SNCAIP and synucleinopathy.